David Malkin

List of Publications by Year in Descending Order

168 papers	9,499 citations	50 h-index	96 g-index
189 ext. papers	11,842 ext. citations	9.9 avg, IF	5.83 L-index

#	Paper	IF	Citations
168	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.. *Nature Medicine*, **2022**,	50.5	2
167	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute.. *Cell Death and Differentiation*, **2022**,	12.7	3
166	Perspectives and Experiences of Parents and Adolescents Who Participate in a Pediatric Precision Oncology Program: "When You Feel Helpless, This Kind of Thing Is Very Helpful".. *JCO Precision Oncology*, **2022**, 6, e2100444	3.6	0
165	Diagnostic accuracy of imaging approaches for early tumor detection in children with Li-Fraumeni syndrome.. *Pediatric Radiology*, **2022**, 1	2.8	0
164	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. *Neuro-Oncology*, **2022**, 24, i107-i107	1	
163	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. *Neuro-Oncology*, **2022**, 24, i81-i81	1	
162	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. *Cancer Discovery*, **2021**, 11, 1176-1191	24.4	19
161	Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status. *Journal of Pediatric Hematology/Oncology*, **2021**, 43, e635-e641	1.2	3
160	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. *JAMA Oncology*, **2021**,	13.4	4
159	Non-rhabdomyosarcoma soft tissue sarcomas diagnosed in patients at a young age. An overview of clinical, pathological, and molecular findings. *Pediatric Blood and Cancer*, **2021**, 68, e29022	3	
158	The transcriptional landscape of Shh medulloblastoma. *Nature Communications*, **2021**, 12, 1749	17.4	7
157	TERT promotor variant associated with poor clinical outcome in a patient with novel RBM15-MKL1 fusion-positive pediatric acute megakaryoblastic leukemia. *Pediatric Blood and Cancer*, **2021**, 68, e28542	3	2
156	Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. *JCO Precision Oncology*, **2021**, 5,	3.6	6
155	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. *Cancer Discovery*, **2021**, 11, 1454-1467	24.4	6
154	Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer. *Familial Cancer*, **2021**, 20, 289-291	3	0
153	Tumor surveillance for children and adolescents with cancer predisposition syndromes: The psychosocial impact reported by adolescents and caregivers. *Pediatric Blood and Cancer*, **2021**, 68, e29021	3	1
152	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. *Journal of Clinical Oncology*, **2021**, 39, 2463-2473	2.2	10

151	Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation.. *JCO Precision Oncology*, **2021**, 5, 1339-1347	3.6	0
150	Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors. *Journal of Clinical Oncology*, **2021**, 39, 3207-3216	2.2	0
149	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. *Journal of Clinical Oncology*, **2021**, 39, 2779-2790	2.2	10
148	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. *Journal of Neuro-Oncology*, **2021**, 155, 63-70	4.8	2
147	Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma. *Cancer Research*, **2021**, 81, 5625-5637	10.1	1
146	Li-Fraumeni Syndrome **2021**, 1-21		
145	Tumour predisposition and cancer syndromes as models to study gene-environment interactions. *Nature Reviews Cancer*, **2020**, 20, 533-549	31.3	32
144	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 927-935	4	3
143	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. *British Journal of Cancer*, **2020**, 122, 1231-1241	8.7	4
142	"Balancing Expectations with Actual Realities": Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. *Journal of Personalized Medicine* , **2020**, 10,	3.6	6
141	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. *Cancer Medicine*, **2020**, 9, 447-459	4.8	6
140	Nearly Half of Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children's Oncology Group. *JCO Precision Oncology*, **2020**, 4,	3.6	3
139	Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes. *Pediatric Blood and Cancer*, **2020**, 67, e28758	3	1
138	Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. *Nature Communications*, **2020**, 11, 3945	17.4	26
137	Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. *Cancers*, **2020**, 12,	6.6	3
136	Cancer surveillance for individuals with Li-Fraumeni syndrome. *European Journal of Human Genetics*, **2020**, 28, 1481-1482	5.3	4
135	Precision Child Health: an Emerging Paradigm for Paediatric Quality and Safety. *Current Treatment Options in Pediatrics*, **2020**, 6, 317-324	0.6	1
134	An eHealth decision-support tool to prioritize referral practices for genetic evaluation of patients with Wilms tumor. *International Journal of Cancer*, **2020**, 146, 1010-1017	7.5	12

133	Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. *Journal of Pathology*, **2019**, 249, 319-331	9.4	19
132	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. *Nature*, **2019**, 572, 67-73	50.4	149
131	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. *Cancer Research*, **2019**, 79, 2208-2219	10.1	3
130	DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies-Response. *Clinical Cancer Research*, **2019**, 25, 1689-1690	12.9	7
129	Management of orbital rhabdomyosarcoma in a child with Li-Fraumeni syndrome. *Journal of AAPOS*, **2019**, 23, 182-185	1.3	1
128	Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. *Pediatric Blood and Cancer*, **2019**, 66, e27629	3	11
127	Report of a bi-allelic truncating germline mutation in TP53. *Familial Cancer*, **2019**, 18, 101-104	3	1
126	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. *Clinical Epigenetics*, **2019**, 11, 117	7.7	12
125	Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. *Clinical Genetics*, **2019**, 96, 461-467	4	7
124	Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. *Cancer*, **2019**, 125, 3514-3525	6.4	51
123	Gliomas in the context of Li-Fraumeni syndrome: An international cohort.. *Journal of Clinical Oncology*, **2019**, 37, 1517-1517	2.2	4
122	Medulloblastoma. *Nature Reviews Disease Primers*, **2019**, 5, 11	51.1	202
121	Parents', Health Care Professionals', and Scientists' Experiences of a Precision Medicine Pilot Trial for Patients With High-Risk Childhood Cancer: A Qualitative Study.. *JCO Precision Oncology*, **2019**, 3, 1-11	3.6	2
120	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. *Nature*, **2019**, 574, 707-711	50.4	78
119	"A change in perspective": Exploring the experiences of adolescents with hereditary tumor predisposition. *Pediatric Blood and Cancer*, **2019**, 66, e27445	3	8
118	Second rhabdoid tumor 8 years after treatment of atypical teratoid/rhabdoid tumor in a child with germline SMARCB1 mutation. *Pediatric Blood and Cancer*, **2019**, 66, e27546	3	8
117	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. *Journal of Neuro-Oncology*, **2019**, 142, 39-48	4.8	14
116	Pediatric oncology clinical trial participation where the geography is vast: Development of a clinical research system for tertiary and satellite centers in Ontario, Canada. *Pediatric Blood and Cancer*, **2018**, 65, e26901	3	2

115	Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma. *Cell Stem Cell*, **2018**, 22, 414-427.e6	18	37
114	Evidence for genetic anticipation in vonHippel-Lindau syndrome. *Journal of Medical Genetics*, **2018**, 55, 395-402	5.8	9
113	and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies. *Clinical Cancer Research*, **2018**, 24, 2251-2261	12.9	169
112	Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma. *Cancer*, **2018**, 124, 1242-1250	6.1	2
111	Family history-taking practices and genetic confidence in primary and tertiary care providers for childhood cancer survivors. *Pediatric Blood and Cancer*, **2018**, 65, e26923	3	5
110	DICER1 syndrome: Approach to testing and management at a large pediatric tertiary care center. *Pediatric Blood and Cancer*, **2018**, 65, e26720	3	29
109	Optimized knock-in of point mutations in zebrafish using CRISPR/Cas9. *Nucleic Acids Research*, **2018**, 46, e102	20.1	26
108	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncology, The*, **2018**, 19, 785-798	21.7	159
107	Retrospective evaluation of a decision-support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors. *Pediatric Blood and Cancer*, **2018**, 65, e27390	3	16
106	Issues in paediatric cancers **2018**, 361-380		
105	ATRT-13. CANCER PREDISPOSITION AMONG CHILDREN WITH RHABDOID TUMORS: A SINGLE-CENTRE RETROSPECTIVE REVIEW. *Neuro-Oncology*, **2018**, 20, i30-i30	1	78
104	Aggressive embryonal rhabdomyosarcoma in a 3-month-old boy: A clinical and molecular analysis. *Pediatric Hematology and Oncology*, **2018**, 35, 407-414	1.7	
103	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. *Neuro-Oncology*, **2018**, 20, i92-i92	1	78
102	Li-Fraumeni Syndrome ? **2018**,		1
101	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. *Patient Preference and Adherence*, **2018**, 12, 2103-2110	2.4	1
100	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. *Science*, **2018**, 361,	33.3	72
99	Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome. *Journal of the National Cancer Institute*, **2018**, 110, 1418-1421	9.7	12
98	The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. *Pediatric Blood and Cancer*, **2017**, 64, e26441	3	19

97	Inherited Mutations and the Li-Fraumeni Syndrome. *Cold Spring Harbor Perspectives in Medicine*, **2017**, 7,	5.4	85
96	Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice. *Cancer Research*, **2017**, 77, 1250-1260	10.1	45
95	Spatial heterogeneity in medulloblastoma. *Nature Genetics*, **2017**, 49, 780-788	36.3	80
94	Pediatric imaging in DICER1 syndrome. *Pediatric Radiology*, **2017**, 47, 1292-1301	2.8	23
93	The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. *Cell Reports*, **2017**, 19, 2304-2318	10.6	34
92	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. *Clinical Cancer Research*, **2017**, 23, e38-e45	12.9	245
91	Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. *Clinical Cancer Research*, **2017**, 23, e1-e5	12.9	83
90	Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. *Pediatric Blood and Cancer*, **2017**, 64, e26340	3	4
89	Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk. *Human Mutation*, **2017**, 38, 265-268	4.7	3
88	Comprehensive Analysis of Hypermutation in Human Cancer. *Cell*, **2017**, 171, 1042-1056.e10	56.2	417
87	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. *JAMA Oncology*, **2017**, 3, 1634-1639	13.4	107
86	Underlying undiagnosed inherited marrow failure syndromes among children with cancer. *Pediatric Blood and Cancer*, **2017**, 64, 302-305	3	5
85	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility. *Journal of Clinical Oncology*, **2016**, 34, 3697-3704	2.2	25
84	Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply. *Lancet Oncology, The*, **2016**, 17, e473	21.7	4
83	p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis. *Cell Cycle*, **2016**, 15, 3210-3219	4.7	39
82	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. *Cancer*, **2016**, 122, 1261-9	6.4	77
81	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
80	Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium. *American Journal of Gastroenterology*, **2016**, 111, 275-84	0.7	26

79	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *Journal of Clinical Oncology*, **2016**, 34, 2206-11	2.2	537
78	Translational Childhood Cancer Genomics: The Future Is Now. *JAMA Oncology*, **2016**, 2, 384-5	13.4	1
77	Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children Oncology Group ARAR0332 protocol.. *Journal of Clinical Oncology*, **2016**, 34, 10515-10515	2.2	10
76	Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network. *Oncotarget*, **2016**, 7, 49611-49622	3.3	8
75	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. *Oncotarget*, **2016**, 7, 28169-82	3.3	44
74	Li-Fraumeni Syndrome and p53 in 2015: Celebrating their Silver Anniversary. *Clinical and Investigative Medicine*, **2016**, 39, E37-47	0.9	8
73	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. *Neuro-Oncology* , **2016**, 18, iii94.1-iii94	1	78
72	PNR-08NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS. *Neuro-Oncology*, **2016**, 18, iii8.2-iii8	1	78
71	Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome. *Human Mutation*, **2016**, 37, 889-92	4.7	7
70	High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. *International Journal of Cancer*, **2016**, 138, 380-5	7.5	48
69	Telomere dysfunction and chromothripsis. *International Journal of Cancer*, **2016**, 138, 2905-14	7.5	34
68	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell*, **2016**, 30, 891-908	24.3	135
67	CANCER. The cancer predisposition revolution. *Science*, **2016**, 352, 1052-3	33.3	10
66	Somatic DICER1 mutations in adult-onset pulmonary blastoma. *European Respiratory Journal*, **2016**, 47, 1879-82	13.6	14
65	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. *Lancet Oncology, The*, **2016**, 17, 1295-305	31.7	266
64	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. *Journal of Clinical Oncology*, **2016**, 34, 4161-4170	2.2	56
63	Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clinical Cancer Research*, **2015**, 21, 184-92	12.9	63
62	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. *European Journal of Cancer*, **2015**, 51, 977-83	7.5	77

61	A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. *Cancer Genetics*, **2015**, 208, 47-51	2.3	28
60	Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. *Cancer Cell*, **2015**, 27, 712-27	24.3	55
59	Ovarian embryonal rhabdomyosarcoma is a rare manifestation of the DICER1 syndrome. *Human Pathology*, **2015**, 46, 917-22	3.7	38
58	Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. *Cancer Medicine*, **2015**, 4, 781-90	4.8	19
57	Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. *Journal of Clinical Oncology*, **2015**, 33, 602-9	2.2	112
56	BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. *Journal of Clinical Oncology*, **2015**, 33, 1015-22	2.2	187
55	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. *Nature Genetics*, **2015**, 47, 257-62	36.3	253
54	Biochemical and imaging surveillance for Li-Fraumeni syndrome: The Toronto Protocol at 11 years.. *Journal of Clinical Oncology*, **2015**, 33, e12546-e12546	2.2	
53	Evaluation of rapid whole-body magnetic resonance as screening strategy for early cancer detection in 57 Brazilian Li-Fraumeni syndrome patients.. *Journal of Clinical Oncology*, **2015**, 33, 1534-1534	2.2	
52	Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. *Journal of Neuro-Oncology*, **2014**, 118, 225-238	4.8	23
51	Management of familial cancer: sequencing, surveillance and society. *Nature Reviews Clinical Oncology*, **2014**, 11, 723-31	19.4	24
50	Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. *Journal of Clinical Oncology*, **2014**, 32, 1760-8	2.2	141
49	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. *European Journal of Cancer*, **2014**, 50, 987-96	7.5	149
48	Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. *Cancer Cell*, **2014**, 26, 33-47	24.3	181
47	Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK?. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, e193-6	1.2	7
46	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. *ELife*, **2014**, 3,	8.9	229
45	Predisposition to pediatric and hematologic cancers: a moving target. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, e44-55	7.1	33
44	Germ-line and somatic DICER1 mutations in pineoblastoma. *Acta Neuropathologica*, **2014**, 128, 583-95	14.3	103

43	Processed pseudogenes acquired somatically during cancer development. *Nature Communications*, **2014**, 5, 3644	17.4	68
42	Attitudes of parents toward the return of targeted and incidental genomic research findings in children. *Genetics in Medicine*, **2014**, 16, 633-40	8.1	67
41	Surveillance for children at genetic risk for cancer: are we ready?. *Pediatric Blood and Cancer*, **2014**, 61, 1337-8	3	4
40	Author response: Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer **2014**,		3
39	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
38	Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting.. *Journal of Clinical Oncology*, **2013**, 31, 10066-10066	2.2	
37	Routine TP53 testing for breast cancer under age 30: ready for prime time?. *Familial Cancer*, **2012**, 11, 607-13	3	67
36	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600
35	Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. *Current Neurology and Neuroscience Reports*, **2012**, 12, 153-64	6.6	18
34	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
33	Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants. *Blood*, **2012**, 120, 2069-2069	2.2	
32	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncology, The*, **2011**, 12, 559-67	21.7	299
31	Imaging of cancer predisposition syndromes in children. *Radiographics*, **2011**, 31, 263-80	5.4	50
30	Reply to J.C. Lindsey et al. *Journal of Clinical Oncology*, **2011**, 29, e347-e347	2.2	1
29	Li-fraumeni syndrome. *Genes and Cancer*, **2011**, 2, 475-84	2.9	265
28	TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. *Journal of Clinical Oncology*, **2010**, 28, 1995-2001	2.2	144
27	Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. *Journal of Clinical Oncology*, **2010**, 28, 1345-50	2.2	124
26	Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. *Cancer Research*, **2010**, 70, 160-71	10.1	137

25	The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. *Cell Cycle*, **2010**, 9, 1951-9	4.7	4
24	Oncogenic ILK, tumor suppression and all that JNK. *Cell Cycle*, **2009**, 8, 4060-6	4.7	17
23	Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. *Pediatric and Developmental Pathology*, **2009**, 12, 127-35	2.2	31
22	Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 11264-9	11.5	155
21	The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen. *Cancer Research*, **2008**, 68, 3476-85	10.1	19
20	The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. *Clinical and Experimental Metastasis*, **2008**, 25, 1-10	4.7	25
19	Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp. *Pediatric Blood and Cancer*, **2007**, 48, 148-51	3	5
18	Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. *Cancer Research*, **2007**, 67, 1415-8	10.1	119
17	Hereditary cancer predisposition in children: genetic basis and clinical implications. *International Journal of Cancer*, **2006**, 119, 2001-6	7.5	83
16	Differentiation of rhabdomyosarcoma cell lines using retinoic acid. *Pediatric Blood and Cancer*, **2006**, 47, 773-84	3	27
15	Predictive genetic testing for childhood cancer: taking the road less traveled by. *Journal of Pediatric Hematology/Oncology*, **2004**, 26, 546-8	1.2	8
14	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. *Experimental Hematology*, **2003**, 31, 693-701	3.1	43
13	Simian virus 40 and non-Hodgkin lymphoma. *Lancet, The*, **2002**, 359, 812-3	40	12
12	The role of p53 in human cancer. *Journal of Neuro-Oncology*, **2001**, 51, 231-43	4.8	40
11	Absence of germline and somatic p53 alterations in children with sporadic brain tumors. *Journal of Neuro-Oncology*, **2001**, 52, 227-35	4.8	15
10	Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. *Oncogene*, **2001**, 20, 4441-9	9.2	55
9	Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. *Medical and Pediatric Oncology*, **2000**, 34, 242-9		16
8	Epstein-Barr virus-associated lymphoproliferative disorder in a child undergoing therapy for localized rhabdomyosarcoma. *Medical and Pediatric Oncology*, **2000**, 34, 358-60		9

7	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. *Oncogene*, **1999**, 18, 3970-8	9.2	30
6	Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. *Childs Nervous System*, **1998**, 14, 590-5	1.7	14
5	Comparison of survival outcomes in patients with intracranial germinomas treated with radiation alone versus reduced-dose radiation and chemotherapy. *Childs Nervous System*, **1998**, 14, 596-601	1.7	36
4	Regulation of cellular proliferation effects on alteration of normal signaling pathways. *Medical and Pediatric Oncology*, **1996**, 27, 20-24		
3	Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. *American Journal of Hematology*, **1994**, 47, 27-32	7.1	28
2	Germline p53 mutations and heritable cancer. *Annual Review of Genetics*, **1994**, 28, 443-65	14.5	61
1	Li Fraumeni Syndrome2, 1-8		